|
Session 10
Oral Abstracts
Antiretroviral Therapy I: New Agents and New Insights
Monday, 10 am - 12:30 pm
Room: Lecture Hall |
Moderators: |
Charles Flexner
Johns Hopkins Univ, Baltimore, MD, US
|
| 10:00 am 45 |
GS9148: A Novel Nucleotide Active against HIV-1 Variants with Drug-resistance Mutations in Reverse Transcriptase
Tomas Cihlar*1, A Ray1, D Boojamra1, L Zhang1, H Hui1, D Grant1, K White1, M Desai1, N Parkin2, and R Mackman1
1Gilead Sci, Foster City, CA, US and 2Monogram Biosci, South San Francisco, CA, US |
| 10:15 am 46 |
1-(ß-D-Dioxolane) Thymine Is Effective against HIV-1-containing TAM and M184V
Johan Lennerstrand*1, G Bluemling1, M Ruckstuhl1, M Bennett1, C Chu2, and R Schinazi1
1Emory Univ and VAMC, Decatur, GA, US and 2Coll of Pharmacy, Univ of Georgia, Athens, US |
| 10:30 am 47 |
Nucleotide-competing Reverse Transcriptase Inhibitors form a Stable Dead-end Complex with the HIV-1 Enzyme
M Ehteshami1, J Deval1, S Barry1, D Jochmans2, K Hertogs2, and Matthias Götte*1
1McGill Univ, Montreal, Canada and 2Tibotec, Mechelen, Belgium |
| 10:45 am 48 |
Next Generation HIV Peptide Fusion Inhibitor Candidates Achieve Potent, Durable Suppression of Virus Replication in vitro and Improved Pharmacokinetic Properties
Mary Delmedico*1, B Bray1, N Cammack2, D Davison1, J Dwyer1, L Frick1, N Tvermoes1, S Wring1, H Zhang1, and M Greenberg1
1Trimeris, Morrisville, NC, US and 2Roche, Palo Alto, CA, US |
| 11:00 am 49LB |
Development of Novel Orally Bioavailable CXCR4 Antagonists, KRH-3955 and KRH-3140: Binding Specificity, Pharmacokinetics and Anti-HIV-1 Activity in vivo and in vitro
Yuetsu Tanaka*1, K Okuma1, R Tanaka1, S Kumakura2, A Shimoyamada2, K Hirose2, M Yanaka2, T Murakami3, and N Yamamoto3
1Univ of the Ryukyus, Okinawa, Japan; 2Kureha Corp. Tokyo, Japan; and 3Natl Inst of Infectious Diseases, Tokyo, Japan |
| 11:15 am 50LB |
Execution of a High Throughput HIV-1 Replication Screen and the Identification of a Novel Small Molecule Inhibitor that Targets HIV-1 Envelope Maturation
Wade Blair*, J Cao, L Jackson, Q Peng, J Isaacson, S Butler, H Wu, A Chu, and A Patick
Pfizer Global Research and Development, La Jolla, CA, |
| 11:30 am 51 |
Toward Gene Knock-out Therapy for AIDS/HIV: Targeted Disruption of CCR5 Using Engineered Zinc Finger Protein Nucleases
Yann Jouvenot*1, E Perez2, F Urnov1, J Miller1, E Rebar1, M Holmes1, D Ando1, J Riley2, P Gregory1, and C June2
1Sangamo Biosci, Port Richmond, CA, US and 2Univ of Pennsylvania, Philadelphia, US |
| 11:00 am 52 |
Pharmacokinetics/Pharmacodynamics of PA-457 in a 10-day Multiple Dose Monotherapy Trial in HIV-infected Patients
Patrick Smith*1, A Forrest1, G Beatty2, J Jacobson3, J Lalezari4, J Eron5, R Pollard6, M Saag7, J Doto8, and D Martin8
1Univ at Buffalo Sch of Pharm, NY, US; 2Univ of California, San Francisco, US; 3Beth Israel Med Ctr, New York, NY, US; 4Quest Clin, San Francisco, CA, US; 5Univ of North Carolina at Chapel Hill, US; 6Univ of California, Davis, US; 7Univ of Alabama at Birmingham, US; and 8Panacos Pharma, Gaithersburg, MD, US |
| 12:00 pm 53 |
The Role of Drug Interaction Studies in Early Antiretroviral Drug Development
Kimberly Struble
Ctr for Drug Evaluation and Res, Food and Drug Admin, Silver Spring, MD, US |
|
